News

October 4, 2021 - Imaging Endpoints congratulates Kite, a Gilead Company (Nasdaq: GILD), on its submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Yescarta® (axicabtagene ciloleucel), based on data from its…   Read More

September 28, 2021 - Imaging Endpoints – in collaboration with Daniel D. Von Hoff, Taylor Brodie, Derek Cridebring and Michael J. Demeure – is presenting at the American Association for Cancer Research’s Pancreatic Cancer Virtual Special Conference September 29-30, 2021.…   Read More

September 23, 2021 - The Imaging Endpoints team works passionately every day to Connect Imaging to the Cure™ and in doing so has helped to bring numerous new, life-saving treatments to humanity. As the largest oncology-focused global iCRO, Imaging Endpoints…   Read More

September 22, 2021 - September is Childhood Cancer Awareness Month. Being diagnosed with cancer is devastating, but it’s even worse when cancer affects a child. Yet, it’s estimated that approximately 10,500 cases of pediatric cancer will be diagnosed in 2021…   Read More

September 16, 2021 - September is Thyroid Cancer Awareness Month. Thyroid Cancer is a devastating disease and is the most common cancer in women aged 20 to 34. Over the last few decades, the incidence of thyroid cancer has increased…   Read More

September 14, 2021 - September is Gynecologic Cancer Awareness Month and Ovarian Cancer Awareness Month. These awareness moments bring particular focus to the important issues of women’s health. Gynecological cancers are known for their poor contrast resolution compared to surrounding…   Read More

September 10, 2021 - RECIST 1.1 and iRECIST are core criteria for advanced clinical trials and their use are extremely important in terms of FDA approval. Samira Farough, MD, our Director of Reader Operations, recently discussed the value of RECIST…   Read More

August 31, 2021 - Blood Cancer takes many devastating forms, such as Lymphocytic or Myeloid Leukemia or Hodgkin or non-Hodgkin Lymphoma. Through our advanced imaging techniques, we are working with clinical researchers on numerous trials to identify safe and effective…   Read More

August 26, 2021 - At Imaging Endpoints, we take cancer personally. We are actively looking for dedicated professionals who share that feeling and have expertise in various fields. Learn more about how you can play an important role and join…   Read More

August 24, 2021 - Imaging Endpoints is consistently outperforming industry standards for reading and response time. We offer same-day, 24-hour and 48-hour responses for eligibility reads and 3 to 5-day response for efficacy reads. Learn more about our industry-leading services…   Read More